An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study
Related Posts
The long trend of falling corporate taxes is being reversed
December 22, 2024
5:12 am
Volkswagen and Unions Enter Fourth Day of Talks
December 22, 2024
4:31 am
Oysters recalled in 3 Canadian provinces over norovirus concerns | Globalnews.ca
December 22, 2024
12:23 am